Search Clinical Trials in the European Union

Duration
Visits
Phase
Oral
Benefits
Drugs
Locations
Clinical Specialty
1661-1680 of 1,694 trials

Choline Alfoscerate for Elderly with Subthreshold Depression

We are studying whether choline alfoscerate can help improve symptoms of subthreshold depression in elderly patients. The trial also looks at its effects on cognitive symptoms and apathy.

Under Threshold Depression in the Elderly1-2 yearsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesPsychiatry

Etrasimod in Breastfeeding Women

We are studying how the medication etrasimod is absorbed into the blood and breast milk of healthy lactating women. This research will help us understand its safety and potential effects on breastfeeding infants.

Ulcerative Colitis1-2 yearsSafety phase (I)No PlaceboStandard MedicinesGastroenterologyGynecology and Obstetrics

Learning Dynamics: Atomoxetine Study

We are investigating how a low dose of atomoxetine affects learning and emotional states in healthy adults. This study aims to understand its impact on learning tasks and emotional well-being.

Healthy Participants>2 yearsEfficacy phase (II)≤5 visitsStandard MedicinesPsychiatry

Idiopathic Hypersomnia: ALKS 2680 Study

We are evaluating a new medication, ALKS 2680, for individuals with Idiopathic Hypersomnia to see if it helps reduce excessive daytime sleepiness and is safe to use.

Idiopathic Hypersomnia3-6 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicineNeurology

Graves' Disease: Rilzabrutinib Study

We are investigating whether rilzabrutinib can help reduce thyroid activity in adults with Graves' disease. The study also aims to evaluate the safety of this new treatment.

Graves' Disease3-6 monthsEfficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesPartially RemoteEndocrinologyInternal Medicine

Pomalidomide for Chronic Hepatitis B Infection

We are studying the safety of pomalidomide in people with chronic hepatitis B. The trial also looks at how this medication may improve immune responses and liver health.

Hepatitis B Virus Infection6-12 monthsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesHepatologyInfectious Diseases

Parkinson's Disease: Lecigon® Therapy

We are studying a new treatment combining levodopa and entacapone for people with Parkinson's disease. The goal is to see if it helps reduce certain symptoms and improve overall well-being compared to standard treatments.

Parkinson's Disease>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesNeurologyPsychiatry

Darolutamide and Bipolar Androgen Therapy for Advanced Prostate Cancer

We are studying whether combining Darolutamide with bipolar androgen therapy improves survival and quality of life for men with metastatic castration-resistant prostate cancer compared to standard treatments.

Metastatic Castration-Resistant Prostate Cancer>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteOncologyUrology

Obesity Treatment: Orforglipron Tablet Study

We are investigating how well a new daily tablet helps people with obesity or overweight, both with and without type 2 diabetes, in reducing weight and improving blood sugar levels compared to a placebo.

ObesityOverweightType 2 Diabetes1-2 yearsConfirmation phase (III)Investigational MedicinesPartially RemoteEndocrinologyInternal Medicine

Non-Small Cell Lung Cancer: RMC-9805 and RMC-6236 Study

We are studying a new treatment combination for patients with RAS G12D-mutant non-small cell lung cancer. The trial will evaluate the safety and effectiveness of these drugs alongside other anticancer therapies.

Non-small Cell Lung Cancer3-6 monthsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncologyPulmonology

Mantle Cell Lymphoma: Acalabrutinib with R-CHOP

We are studying the combination of acalabrutinib and R-CHOP for patients with previously untreated mantle cell lymphoma. The goal is to see if this combination improves treatment response and is safe.

Mantle Cell Lymphoma>2 yearsEfficacy phase (II)16-20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesHematologyOncology

Chronic Subdural Hematoma: Timing of Anticoagulation

We are studying whether starting blood-thinning medication early or later helps patients with atrial fibrillation recover better after surgery for chronic subdural hematoma. This research looks at potential risks and overall health outcomes.

Chronic Subdural HematomaAtrial Fibrillation3-6 monthsEfficacy phase (II)Confirmation phase (III)No PlaceboStandard MedicinesPartially RemoteCardiologyInternal MedicineNeurology

Type 2 Diabetes: Vicadrostat and Empagliflozin Study

We are testing the combination of vicadrostat and empagliflozin in people with type 2 diabetes, high blood pressure, and heart disease. The goal is to see if this combination can improve heart health compared to a placebo.

Type 2 DiabetesHypertensionCardiovascular Disease>2 yearsConfirmation phase (III)Investigational MedicinesCost ReimbursementPartially RemoteCardiologyEndocrinologyInternal Medicine

Immunotherapy for Metastatic Colorectal and Prostate Cancer

We are studying a new treatment using patients' own immune cells to see if it is safe and tolerable for those with advanced colorectal or prostate cancer. The trial will help us understand how well this therapy works in these patients.

Locally Advanced or Metastatic Prostate CancerMetastatic Colorectal Cancer>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesPartially RemoteGastroenterologyOncologyUrology

Birth Control Study: Levonorgestrel Tablet

We are investigating whether the Levonorgestrel tablet can still prevent ovulation despite planned delays in taking the pill. This study is for individuals interested in understanding the reliability of this contraceptive method.

Ovulation Inhibition6-12 monthsEfficacy phase (II)No PlaceboStandard MedicinesGynecology and Obstetrics

Advanced Solid Tumors: S095035 Treatment Study

We are investigating the safety and effectiveness of S095035, alone and with TNG462, for adults with advanced solid tumors that have a specific genetic deletion. This study aims to find the best dose and assess how well the treatment works.

Malignant Solid TumorSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteOncology

Atrial Fibrillation: Early Rhythm-Control Therapy for Stroke Prevention

We are studying if starting rhythm-control therapy early helps patients with atrial fibrillation after a stroke avoid further heart problems. This trial also examines the impact on quality of life and treatment costs.

Acute Ischemic Stroke and Atrial Fibrillation>2 yearsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesPartially RemoteCardiologyInternal Medicine

Atrial Fibrillation: Amiodarone Administration Study

We are comparing intravenous and enteral amiodarone in critically ill patients with new-onset atrial fibrillation. The goal is to see which method is more effective in restoring normal heart rhythm and improving overall health.

Atrial Fibrillation with Rapid Ventricular Response≤3 monthsMonitoring phase (IV)No PlaceboInvestigational MedicinesCardiologyInternal Medicine

Lactose Intolerance Diagnosis: LacTEST for Children

We are studying the LacTEST to see if it accurately diagnoses lactose intolerance in children aged 5 to 11. The trial will also check the test's safety and whether a shorter urine collection time is effective.

Lactose Intolerance≤3 monthsMonitoring phase (IV)≤5 visitsNo PlaceboInvestigational MedicinesPartially RemoteGastroenterologyPediatrics

Atrial Fibrillation: AP31969 Medication Study

We are testing a new medication, AP31969, for people with atrial fibrillation to see if it helps control their heart rhythm and improve their quality of life. The study will also evaluate the safety of this treatment.

Atrial Fibrillation3-6 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesCardiologyInternal Medicine